Skip to main content
Journal cover image

Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.

Publication ,  Journal Article
Landstrom, AP; Tefferi, A
Published in: Leuk Lymphoma
March 2006

The unique molecular characteristic of chronic myeloid leukemia (CML), the disease-causing ABL (9q34) to BCR (22q11) translocation, has provided an invaluable tool for disease diagnosis and monitoring of treatment response. The traditional standard in this regard is bone marrow karyotype, also known as conventional cytogenetics (CC), which reveals a shortened chromosome 22, the Philadelphia chromosome, t(9;22)(q34;q11). CC in CML has also been effectively used for monitoring the response to drug therapy. However, this particular laboratory test misses submicroscopic BCR/ABL translocations and is suboptimal for minimal residual disease (MRD) assessment. Both fluorescence in situ hybridization (FISH) and reverse-transcriptase polymerase chain reaction (RT-PCR) feature higher sensitivity in terms of both diagnosis and MRD assessment in CML, compared to CC. Another advantage of these alternative tests is their effective applicability to peripheral blood specimens. The current review highlights the practical literature with respect to the use of FISH for CML whereas the use of RT-PCR has been extensively covered in recent communications.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Lymphoma

DOI

ISSN

1042-8194

Publication Date

March 2006

Volume

47

Issue

3

Start / End Page

397 / 402

Location

United States

Related Subject Headings

  • Reverse Transcriptase Polymerase Chain Reaction
  • Prognosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • In Situ Hybridization, Fluorescence
  • Immunology
  • Humans
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Landstrom, A. P., & Tefferi, A. (2006). Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma, 47(3), 397–402. https://doi.org/10.1080/10428190500353133
Landstrom, Andrew P., and Ayalew Tefferi. “Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.Leuk Lymphoma 47, no. 3 (March 2006): 397–402. https://doi.org/10.1080/10428190500353133.
Landstrom, Andrew P., and Ayalew Tefferi. “Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.Leuk Lymphoma, vol. 47, no. 3, Mar. 2006, pp. 397–402. Pubmed, doi:10.1080/10428190500353133.
Journal cover image

Published In

Leuk Lymphoma

DOI

ISSN

1042-8194

Publication Date

March 2006

Volume

47

Issue

3

Start / End Page

397 / 402

Location

United States

Related Subject Headings

  • Reverse Transcriptase Polymerase Chain Reaction
  • Prognosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • In Situ Hybridization, Fluorescence
  • Immunology
  • Humans
  • 3201 Cardiovascular medicine and haematology
  • 1103 Clinical Sciences